Abstract |
The aim of this study was to evaluate the effect of PXF (1800 mg daily) in patients with sudden loss of vision (SLV) in a 4-week trial, evaluating clinical outcome and retinal flow parameters. Inclusion criteria were SLV associated with thrombosis of the retinal artery; decrease in retinal blood flow (PSF: peak-systolic flow; EDF: end-diastolic flow velocity) and asymmetry between the two retinal arteries (>40%) documented by duplex scanning. All 10 included patients completed the study. The groups were comparable. No side effects were reported. A significant improvement in flow velocity (p<0.05) and a decrease in analogue score in both groups were observed. PSF increase was 550% in the PXF group vs 288% in the placebo group (262% difference). EDF increase was 400% in the PXF group vs 200% in the placebo group (200% difference). There was a significant difference in the analogue score decrease (33.3% difference larger in the PXF group; p<0.05). In conclusion, PXF treatment improved retinal flow after retinal artery occlusion better than placebo and should be considered as an important option in this condition.
|
Authors | L Incandela, M R Cesarone, G Belcaro, R Steigerwalt, M T De Sanctis, A N Nicolaides, M Griffin, G Geroulakos, G Ramaswami |
Journal | Angiology
(Angiology)
2002 Jan-Feb
Vol. 53 Suppl 1
Pg. S31-4
ISSN: 0003-3197 [Print] United States |
PMID | 11865833
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Vasodilator Agents
- Pentoxifylline
|
Topics |
- Blood Flow Velocity
(drug effects, physiology)
- Female
- Hemorheology
(drug effects)
- Humans
- Male
- Middle Aged
- Pentoxifylline
(therapeutic use)
- Retinal Artery
(drug effects, physiopathology)
- Retinal Artery Occlusion
(drug therapy, physiopathology)
- Time Factors
- Treatment Outcome
- Vascular Diseases
(drug therapy, physiopathology)
- Vasodilator Agents
(therapeutic use)
|